KDR and neoplasm: Sorafenib is a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and Raf kinases, and its anti-tumor mechanism includes stromal effects such as anti-angiogenesis and direct anti-proliferative and pro-apoptotic effects on tumor cells [1].